{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:02:21Z","timestamp":1784559741411,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08219-6","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:27:13Z","timestamp":1779776833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin-Yue","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Qi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie-Yuan","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-0605","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"4","key":"8219_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"8219_CR2","doi-asserted-by":"crossref","unstructured":"Engin A. Nonalcoholic fatty liver disease and staging of hepatic fibrosis. Adv Exp Med Biol. 2024;1460(539\u201374.","DOI":"10.1007\/978-3-031-63657-8_18"},{"issue":"1","key":"8219_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s42000-021-00339-6","volume":"21","author":"I Vachliotis","year":"2022","unstructured":"Vachliotis I, Goulas A, Papaioannidou P, Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Horm (Athens). 2022;21(1):41\u201349. https:\/\/doi.org\/10.1007\/s42000-021-00339-6.","journal-title":"Horm (Athens)"},{"issue":"5","key":"8219_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepatology"},{"key":"8219_CR5","doi-asserted-by":"publisher","unstructured":"A call for unity: the path towards a more precise and patient-centric nomenclature for NAFLD. Ann Hepatol. 2023;28(4):101115. https:\/\/doi.org\/10.1016\/j.aohep.2023.101115.","DOI":"10.1016\/j.aohep.2023.101115"},{"key":"8219_CR6","doi-asserted-by":"publisher","unstructured":"Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:122(3\u201312210. https:\/\/doi.org\/10.1016\/j.ejim.2023.11.005.","DOI":"10.1016\/j.ejim.2023.11.005"},{"issue":"113869","key":"8219_CR7","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar S, Duan Q, Wu R, Harris EN, Su Q. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 2021;176(113869):113869. https:\/\/doi.org\/10.1016\/j.addr.2021.113869.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"8219_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913\u201328. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.311.","journal-title":"Gastroenterology"},{"issue":"2","key":"8219_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study Group. Hepatology. 1996;24(2):289\u201393. https:\/\/doi.org\/10.1002\/hep.510240201.","journal-title":"Hepatology"},{"key":"8219_CR10","unstructured":"World Health Organization. DB93.0 hepatic fibrosis for ICD-11 for mortality and morbidity statistics, 2025. Available website: https:\/\/icd.who.int\/browse11\/l-m\/en#\/http:\/\/id.who.int\/icd\/entity\/1377614074."},{"issue":"3","key":"8219_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Educ Chang Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Educ Chang Hepatol"},{"key":"8219_CR12","doi-asserted-by":"publisher","unstructured":"Sohn W, Lee YS, Kim SS, Kim JH, Jin YJ, Kim GA, et al. KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol. 2025;31(Suppl):S1\u2013s31. https:\/\/doi.org\/10.3350\/cmh.2025.0045.","DOI":"10.3350\/cmh.2025.0045"},{"key":"8219_CR13","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Available website: https:\/\/www.fda.gov\/news-events\/pressannouncements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. 11 Dec 2024."},{"key":"8219_CR14","unstructured":"U.S. Food and Drug Administration. FDA approves treatment for serious liver disease known as \u2018MASH\u2019. Available website: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. 15 Aug 2025."},{"issue":"6","key":"8219_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R. Comparison of pharmacological therapies in metabolic dysfunction\u2013associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology. 2025;82(6):1523\u201333. https:\/\/doi.org\/10.1097\/HEP.0000000000001254.","journal-title":"Hepatology"},{"issue":"11","key":"8219_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"6","key":"8219_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease\u2020. Hepatology. 2005;41(6):1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"issue":"1","key":"8219_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","volume":"115","author":"DA Simonetto","year":"2020","unstructured":"Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am. J. Gastroenterol. 2020;115(1):18\u201340. https:\/\/doi.org\/10.14309\/ajg.0000000000000486.","journal-title":"Am. J. Gastroenterol"},{"key":"8219_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366((l4898)):l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"11","key":"8219_CR20","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/sim.1188","volume":"21","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21(11):1575\u2013600. https:\/\/doi.org\/10.1002\/sim.1188.","journal-title":"Stat Med"},{"issue":"3","key":"8219_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Multiling Evidence-Based Healthcare. 2015;13(3):196\u2013207. https:\/\/doi.org\/10.1097\/XEB.0000000000000065.","journal-title":"Int J Multiling Evidence-Based Healthcare"},{"issue":"20","key":"8219_CR22","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/sim.4172","volume":"30","author":"D Jackson","year":"2011","unstructured":"Jackson D, Riley R, White IR. Multivariate meta-analysis: potential and promise. Stat Med. 2011;30(20):2481\u201398. https:\/\/doi.org\/10.1002\/sim.4172.","journal-title":"Stat Med"},{"issue":"2","key":"8219_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397. https:\/\/doi.org\/10.1002\/jrsm.1037.","journal-title":"Res Synth Methods"},{"key":"8219_CR24","doi-asserted-by":"publisher","unstructured":"Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ. 2011;343(aug16 2):d4909\u20134909. https:\/\/doi.org\/10.1136\/bmj.d4909.","DOI":"10.1136\/bmj.d4909"},{"issue":"1","key":"8219_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79. https:\/\/doi.org\/10.1186\/s13643-017-0473-z.","journal-title":"Syst Rev"},{"issue":"2","key":"8219_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325. https:\/\/doi.org\/10.1002\/jrsm.1045.","journal-title":"Res Synth Methods"},{"issue":"10","key":"8219_CR27","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","volume":"27","author":"V Ratziu","year":"2021","unstructured":"Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021;27(10):1825\u201335. https:\/\/doi.org\/10.1038\/s41591-021-01495-3.","journal-title":"Nat Med"},{"issue":"8","key":"8219_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psp4.12091","volume":"5","author":"D Mawdsley","year":"2016","unstructured":"Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ. Model-based network meta-analysis: A Framework for evidence synthesis of clinical trial data. CPT Pharmacom Syst Pharma. 2016;5(8):393\u2013401. https:\/\/doi.org\/10.1002\/psp4.12091.","journal-title":"CPT Pharmacom Syst Pharma"},{"issue":"2","key":"8219_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/0962280216637093","volume":"27","author":"O Langford","year":"2018","unstructured":"Langford O, Aronson JK, van Valkenhoef G, Stevens RJ. Methods for meta-analysis of pharmacodynamic dose\u2013response data with application to multi-arm studies of alogliptin. Stat Methods Med Res. 2018;27(2):564\u201378. https:\/\/doi.org\/10.1177\/0962280216637093.","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"8219_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/pst.432","volume":"10","author":"S Kirby","year":"2011","unstructured":"Kirby S, Brain P, Jones B. Fitting E max models to clinical trial dose\u2013response data. Pharm Stat. 2011;10(2):143\u201349. https:\/\/doi.org\/10.1002\/pst.432.","journal-title":"Pharm Stat"},{"issue":"10215","key":"8219_CR31","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7.","journal-title":"Lancet"},{"issue":"3","key":"8219_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Sanyal A, Harrison SA, Wong VW-S, Francque S, Goodman Z, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72(3):892\u2013905. https:\/\/doi.org\/10.1002\/hep.31108.","journal-title":"Hepatology"},{"issue":"5","key":"8219_CR33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Educ Chang Hepatol. 2020;72(5):816\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.024.","journal-title":"J Educ Chang Hepatol"},{"issue":"7","key":"8219_CR34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262\u201371. https:\/\/doi.org\/10.1038\/s41591-021-01425-3.","journal-title":"Nat Med"},{"issue":"12","key":"8219_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. LancetThe Lancet Gastroenterol Hepatol. 2023;8(12):1080\u201393. https:\/\/doi.org\/10.1016\/S2468-1253(23)00272-8.","journal-title":"LancetThe Lancet Gastroenterol Hepatol"},{"issue":"5","key":"8219_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","volume":"78","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, et al. Evaluation of PXL065 \u2013 deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). J Educ Chang Hepatol. 2023;78(5):914\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004.","journal-title":"J Educ Chang Hepatol"},{"issue":"12","key":"8219_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","volume":"9","author":"R Loomba","year":"2024","unstructured":"Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W, et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. LancetThe Lancet Gastroenterol & Hepatol. 2024;9(12):1090\u2013100. https:\/\/doi.org\/10.1016\/S2468-1253(24)00246-2.","journal-title":"LancetThe Lancet Gastroenterol & Hepatol"},{"issue":"4","key":"8219_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"1","key":"8219_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","volume":"22","author":"R Loomba","year":"2024","unstructured":"Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clin Gastroenterol Hepatol. 2024;22(1):102\u201312.e9. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"8219_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/HEP.0000000000000723","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Francque S, Behling CA, Cejvanovic V, Cortez-Pinto H, Iyer JS, et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology. 2024;80(1):173\u201385. https:\/\/doi.org\/10.1097\/HEP.0000000000000723.","journal-title":"Hepatology"},{"issue":"4","key":"8219_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"2","key":"8219_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","volume":"83","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, Tai D, Wack K, et al. A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH. J Educ Chang Hepatol. 2025;83(2):293\u2013303. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.032.","journal-title":"J Educ Chang Hepatol"},{"issue":"6","key":"8219_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"101633","key":"8219_CR44","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.molmet.2022.101633","volume":"66","author":"T Zimmermann","year":"2022","unstructured":"Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66(101633):101633. https:\/\/doi.org\/10.1016\/j.molmet.2022.101633.","journal-title":"Mol Metab"},{"issue":"3","key":"8219_CR45","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep.28962","volume":"65","author":"MP Valdecantos","year":"2017","unstructured":"Valdecantos MP, Pardo V, Ruiz L, Castro-S\u00e1nchez L, Lanz\u00f3n B, Fern\u00e1ndez-Mill\u00e1n E, et al. A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology. 2017;65(3):950\u201368. https:\/\/doi.org\/10.1002\/hep.28962.","journal-title":"Hepatology"},{"issue":"11","key":"8219_CR46","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijms25115640","volume":"25","author":"P Portincasa","year":"2024","unstructured":"Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, et al. Metabolic dysfunction\u2013associated steatotic liver disease: from pathogenesis to Current therapeutic options. IJMS. 2024;25(11):5640. https:\/\/doi.org\/10.3390\/ijms25115640.","journal-title":"IJMS"},{"issue":"10","key":"8219_CR47","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/biomedicines12102328","volume":"12","author":"H Ayesh","year":"2024","unstructured":"Ayesh H, Beran A, Suhail S, Ayesh S, Niswender K. Comparative analysis of resmetirom vs. FGF21 Analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials. FGF21 Analogs Vs. GLP-1 Agonists MASLD MASH: Network Meta-Anal Clin Trials. Biomedicines. 2024;12(10):2328. https:\/\/doi.org\/10.3390\/biomedicines12102328.","journal-title":"FGF21 Analogs Vs. GLP-1 Agonists MASLD MASH: Network Meta-Anal Clin Trials. Biomedicines"},{"issue":"3","key":"8219_CR48","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Rolph T, Knott M, Dubourg J. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Educ Chang Hepatol. 2024;81(3):562\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.034.","journal-title":"J Educ Chang Hepatol"},{"key":"8219_CR49","doi-asserted-by":"publisher","unstructured":"Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front. Endocrinol. 2020;11(601290). https:\/\/doi.org\/10.3389\/fendo.2020.601290.","DOI":"10.3389\/fendo.2020.601290"},{"issue":"4","key":"8219_CR50","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","volume":"1","author":"A Kaufman","year":"2020","unstructured":"Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid Metabolism in type 2 diabetes patients. Cell Rep. Med. 2020;1(4):100057. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100057.","journal-title":"Cell Rep. Med"},{"issue":"5","key":"8219_CR51","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1210\/en.2016-1917","volume":"158","author":"S Stanislaus","year":"2017","unstructured":"Stanislaus S, Hecht R, Yie J, Hager T, Hall M, Spahr C, et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology. 2017;158(5):1314\u201327. https:\/\/doi.org\/10.1210\/en.2016-1917.","journal-title":"Endocrinology"},{"issue":"1","key":"8219_CR52","doi-asserted-by":"publisher","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","volume":"12","author":"M O\u2019Farrell","year":"2022","unstructured":"O\u2019Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, et al. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep. 2022;12(1):15661. https:\/\/doi.org\/10.1038\/s41598-022-19459-z.","journal-title":"Sci Rep"},{"issue":"2","key":"8219_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S2468-1253(24)00388-1","volume":"10","author":"X Li","year":"2025","unstructured":"Li X, Ayada I, Li P, Pan Q. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis. LancetThe Lancet Gastroenterol Hepatol. 2025;10(2):108\u201309. https:\/\/doi.org\/10.1016\/S2468-1253(24)00388-1.","journal-title":"LancetThe Lancet Gastroenterol Hepatol"},{"issue":"1","key":"8219_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt.15030","volume":"49","author":"M Shiffman","year":"2019","unstructured":"Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2019;49(1):64\u201373. https:\/\/doi.org\/10.1111\/apt.15030.","journal-title":"Aliment. Pharmacol. Ther"},{"issue":"156043","key":"8219_CR55","doi-asserted-by":"publisher","first-page":"156043","DOI":"10.1016\/j.metabol.2024.156043","volume":"161","author":"RT Lin","year":"2024","unstructured":"Lin RT, Sun QM, Xin X, Ng CH, Valenti L, Hu YY, et al. Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis. Metabolism. 2024;161(156043):156043. https:\/\/doi.org\/10.1016\/j.metabol.2024.156043.","journal-title":"Metabolism"},{"key":"8219_CR56","doi-asserted-by":"publisher","unstructured":"Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11(6):e0158156. https:\/\/doi.org\/10.1371\/journal.pone.0158156.","DOI":"10.1371\/journal.pone.0158156"},{"issue":"8","key":"8219_CR57","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/hep4.1723","volume":"5","author":"V Jacques","year":"2021","unstructured":"Jacques V, Bolze S, Hallakou-Bozec S, Czarnik AW, Divakaruni AS, Fouqueray P, et al. Deuterium-stabilized (R)-pioglitazone (PXL065) is responsible for pioglitazone efficacy in NASH yet exhibits little to No PPAR\u03b3 activity. Hepatol Commun. 2021;5(8):1412\u201325. https:\/\/doi.org\/10.1002\/hep4.1723.","journal-title":"Hepatol Commun"},{"key":"8219_CR58","doi-asserted-by":"publisher","unstructured":"Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8(1). https:\/\/doi.org\/10.1621\/nrs.08005.","DOI":"10.1621\/nrs.08005"},{"issue":"5","key":"8219_CR59","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127(5):1497\u2013512. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.001.","journal-title":"Gastroenterology"},{"issue":"4","key":"8219_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463\u201372. https:\/\/doi.org\/10.1136\/gut.2010.212159.","journal-title":"Gut"},{"issue":"5","key":"8219_CR61","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor \u03baB in hepatic inflammatory response. Hepatology. 2008;48(5):1632\u201343. https:\/\/doi.org\/10.1002\/hep.22519.","journal-title":"Hepatology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08219-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:14:17Z","timestamp":1784556857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08219-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8219"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08219-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used data from publicly published studies and, therefore, did not require ethics committee approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"931"}}